Hua Medicine (Shanghai) Yönetim
Yönetim kriter kontrolleri 3/4
Hua Medicine (Shanghai)'s CEO is Li Chen, appointed in Jun 2010, has a tenure of 14.42 years. total yearly compensation is CN¥17.08M, comprised of 33.6% salary and 66.4% bonuses, including company stock and options. directly owns 3.96% of the company’s shares, worth HK$67.19M. The average tenure of the management team and the board of directors is 4.8 years and 6.2 years respectively.
Anahtar bilgiler
Li Chen
İcra Kurulu Başkanı
CN¥17.1m
Toplam tazminat
| CEO maaş yüzdesi | 33.6% |
| CEO görev süresi | 14.4yrs |
| CEO sahipliği | 4.0% |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 6.2yrs |
Son yönetim güncellemeleri
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥263m |
| Mar 31 2024 | n/a | n/a | -CN¥237m |
| Dec 31 2023 | CN¥17m | CN¥6m | -CN¥211m |
| Sep 30 2023 | n/a | n/a | -CN¥200m |
| Jun 30 2023 | n/a | n/a | -CN¥189m |
| Mar 31 2023 | n/a | n/a | -CN¥196m |
| Dec 31 2022 | CN¥23m | CN¥5m | -CN¥204m |
| Sep 30 2022 | n/a | n/a | -CN¥234m |
| Jun 30 2022 | n/a | n/a | -CN¥265m |
| Mar 31 2022 | n/a | n/a | -CN¥295m |
| Dec 31 2021 | CN¥24m | CN¥5m | -CN¥326m |
| Sep 30 2021 | n/a | n/a | -CN¥355m |
| Jun 30 2021 | n/a | n/a | -CN¥385m |
| Mar 31 2021 | n/a | n/a | -CN¥389m |
| Dec 31 2020 | CN¥28m | CN¥5m | -CN¥393m |
| Sep 30 2020 | n/a | n/a | -CN¥378m |
| Jun 30 2020 | n/a | n/a | -CN¥363m |
| Mar 31 2020 | n/a | n/a | -CN¥394m |
| Dec 31 2019 | CN¥28m | CN¥4m | -CN¥425m |
| Sep 30 2019 | n/a | n/a | -CN¥1b |
| Jun 30 2019 | n/a | n/a | -CN¥2b |
| Mar 31 2019 | n/a | n/a | -CN¥3b |
| Dec 31 2018 | CN¥12m | CN¥2m | -CN¥4b |
| Sep 30 2018 | n/a | n/a | -CN¥3b |
| Jun 30 2018 | n/a | n/a | -CN¥2b |
| Mar 31 2018 | n/a | n/a | -CN¥440m |
| Dec 31 2017 | CN¥4m | CN¥3m | -CN¥273m |
Tazminat ve Piyasa: Li's total compensation ($USD2.41M) is above average for companies of similar size in the Hong Kong market ($USD359.95K).
Tazminat ve Kazançlar: Li's compensation has been consistent with company performance over the past year.
CEO
Li Chen (61 yo)
14.4yrs
Görev süresi
CN¥17,083,000
Tazminat
Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and served as its Chief Scientific Officer until 2022 and served as its President until May 19, 2016 and has been its Chief Executive Of...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 14.4yrs | CN¥17.08m | 3.96% HK$ 67.2m | |
| Executive VP & Chief Strategy Officer | 1.7yrs | CN¥7.16m | 0.87% HK$ 14.7m | |
| CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA | 4.8yrs | Veri yok | Veri yok | |
| Chief Scientific Officer | 1.9yrs | Veri yok | Veri yok | |
| Head of IR | no data | Veri yok | Veri yok | |
| Senior VP of Pharma Development | 6.6yrs | Veri yok | Veri yok | |
| VP of Quality Assurance Division & Chief Quality Officer | 1.5yrs | Veri yok | Veri yok | |
| Company Secretary | 4.9yrs | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: 2552's management team is considered experienced (4.8 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 14.4yrs | CN¥17.08m | 3.96% HK$ 67.2m | |
| Senior VP of Pharma Development | less than a year | Veri yok | Veri yok | |
| Non-Executive Chairman | 14.6yrs | Veri yok | 0.015% HK$ 259.5k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 6.2yrs | CN¥450.00k | 0.0024% HK$ 41.6k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 6.2yrs | CN¥540.00k | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 1.8yrs | CN¥540.00k | Veri yok | |
| Non-Executive Director | 1.1yrs | Veri yok | Veri yok |
6.2yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 2552's board of directors are considered experienced (6.2 years average tenure).